Table 2.
Changes in urine in response to dDAVP in response to dDAVP administered alone (control period, day 4) or after 7-day pretreatment with amiloride (amiloride period, day 14) in 47 healthy subjects on a high Na/low K diet
| Control Period (Day 4) | Amiloride (Day 14) | ||
|---|---|---|---|
| Flow rate (ml/min) | Before dDAVP | 5.9 [4.1, 8.0] | 5.6 [3.9, 7.0] |
| After dDAVP | 1.2 [1.1, 1.6]b | 1.3 [1.0, 1.7]b | |
| Uosm (mosmol/kg H2O) | Before dDAVP | 137 [117, 211] | 165 [126, 222] |
| After dDAVP | 588 [487, 636]b | 630 [545, 723]b | |
| UcreatV (μmol/min) | Before dDAVP | 9.5 [8.0, 10.7] | 9.2 [7.7, 10.6] |
| After dDAVP | 12.1 [10.9, 14.0]b | 11.6 [10.7, 13.1]b | |
| UNaV (μmol/min) | Before dDAVP | 249 [186, 308] | 254 [194, 343] |
| After dDAVP | 193 [139, 236]a | 234 [190, 300] | |
| UKV (μmol/min) | Before dDAVP | 75 [62, 90] | 61 [46, 76] |
| After dDAVP | 70 [60, 87] | 53 [39, 75] | |
| UNa/UK (mmol/mmol) | Before dDAVP | 3.2 [2.7, 3.9] | 4.1 [3.3, 5.2] |
| After dDAVP | 2.5 [2.2, 3.2]b | 4.4 [3.3, 6.2] | |
| Ccreat (ml/min) | Before dDAVP | 118 [98, 138] | 113 [94, 134] |
| After dDAVP | 153 [138, 178]b | 144 [136, 165]b | |
| Cosm (ml/min) | Before dDAVP | 3.1 [2.5, 3.8] | 3.5 [2.6, 3.8] |
| After dDAVP | 2.6 [2.2, 3.0]b | 2.9 [2.6, 3.5]a | |
| CH2O (ml/min) | Before dDAVP | 3.0 [0.9, 4.4] | 2.4 [0.4, 3.3] |
| After dDAVP | −1.3 [−1.5, −1.0]b | −1.6 [−1.9, −1.2]b | |
| TTKG | Before dDAVP | 6.6 [5.3, 7.6] | 4.5 [3.7, 5.7] |
| After dDAVP | 7.8 [6.3, 8.9]b | 4.2 [3.4, 5.7] |
Uosm, urinary osmolality; UNaV, urinary sodium excretions; UKV, urinary potassium excretions; UcreatV, urinary creatinine excretions; Ccreat, creatinine clearances, Cosm, osmolar clearances; CH2O, free water clearances; TTKG, transtubular potassium gradient (see Materials and Methods section). Data are median [IQR].
a
P < 0.05 after versus before dDAVP.
b
P < 0.001 after versus before dDAVP.